Research & Development

Dewpoint Therapeutics secures funding for DPTX3186 development

Dewpoint Therapeutics has secured funding in a Series D funding round, which will support the progression of DPTX3186, a condensate modulator (c-mod), into clinical studies by 2025-end.

Novonesis and Novo Nordisk collaborate on gut microbiome research initiative

Novonesis and Novo Nordisk have formed a research partnership to investigate the role of the gut microbiome in sustaining metabolic health.

FDA grants breakthrough therapy status to Eli Lilly’s olomorasib

Eli Lilly has received the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to olomorasib, an investigational KRAS G12C inhibitor.

OMass signs deal with Genentech for IBD small molecules

OMass Therapeutics in the UK has signed an exclusive collaboration and licensing agreement with Roche Group member Genentech to develop and commercialise inflammatory bowel disease (IBD) therapies.

Biosynth opens expanded GMP bioconjugation facility in Germany

Biosynth, a supplier of essential raw materials and services for the life sciences and diagnostics sectors, has opened an expanded good manufacturing practice (GMP) bioconjugation facility at its Berlin site in Germany.

PCI completes acquisition of sterile fill-finish CDMO Ajinomoto Althea

PCI Pharma Services (PCI) has concluded the acquisition of Ajinomoto Althea, a sterile fill-finish contract development and manufacturing organisation (CDMO) based in the US.

Parvus and Resilience expand partnership to develop IBD drug candidate

Clinical-stage company Parvus Therapeutics has expanded its collaboration with biomanufacturing company National Resilience to develop and manufacture the autoimmune drug candidate, PVT401, for inflammatory bowel disease (IBD).

Ring Therapeutics signs partnerships to advance R&D in biomedical sciences

Ring Therapeutics has entered into new strategic partnerships with the Agency for Science, Technology, and Research (A*STAR) and the Singapore Eye Research Institute (SERI) to enhance research and development (R&D) efforts in the biomedical sciences sector.

insitro collaborates with Lilly on metabolic disease treatments

Machine learning-enabled drug discovery and development company insitro has executed three agreements with Lilly to advance new treatments for metabolic diseases.